Lucid Diligence Brief: Cullinan Therapeutics Gains FDA Orphan Drug Designation for CLN-049
Lucid Diligence Brief: Cullinan Therapeutics Receives FDA Orphan Drug…
Lucid Diligence Brief: Plus Therapeutics and Ephemeral AI Partnership in CNS Oncology
Lucid Diligence Brief: Plus Therapeutics and Ephemeral AI partnership raises…
Lucid Diligence Brief: Helio Genomics and Syneos Health Deal
Lucid Diligence Brief: Helio Genomics and Syneos Health Deal to expand…
Lucid Diligence Brief: Regeneron collaboration with Parabilis Medicines
Lucid Diligence Brief: Regeneron collaboration with Parabilis Medicines…
Lucid Diligence Brief: Iterative Health Acquisition of NextStage Cardiology Research Sites
Lucid Diligence Brief: Iterative Health Acquisition of NextStage Cardiology…
Lucid Diligence Brief: ERS Genomics and Aurigene CRISPR/Cas9 License
Lucid Diligence Brief: ERS Genomics’ CRISPR/Cas9 IP license to Aurigene raises…
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic partnership for late-phase AAV manufacturing
Lucid Diligence Brief: Catalent and Elpida Therapeutics announced a strategic…
Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition
Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition…
Lucid Diligence Brief: Lucent Diagnostics and Tempus AI Partnership
Lucid Diligence Brief: Lucent Diagnostics and Tempus AI Partnership…
Lucid Diligence Brief: Blackstone Life Sciences $250 million investment in Anagram Therapeutics
Lucid Diligence Brief: Blackstone Life Sciences $250 million investment in…
Lucid Diligence Brief: Roche to acquire PathAI
Lucid Diligence Brief: Roche acquires PathAI for USD 1.05B to advance AI…
Lucid Diligence Brief: SiranBio and GSK SA030 Licensing Agreement
Lucid Diligence Brief: SiranBio and GSK SA030 Licensing Agreement Professional…